Advertisement

Table of Contents

May 01, 1996; Volume 49,Issue 5

You have access
5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
X J Yu, C Waeber, N Castanon, K Scearce, R Hen, J E Macor, J Chauveau, M A Moskowitz and J Chaveau

Molecular Pharmacology May 1996, 49 (5) 761-765;
You have access
DNA repair activity in protein extracts of fresh human malignant lymphoid cells.
J M Barret, P Calsou, G Laurent and B Salles

Molecular Pharmacology May 1996, 49 (5) 766-771;
You have access
Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
A Skladanowski, S Y Plisov, J Konopa and A K Larsen

Molecular Pharmacology May 1996, 49 (5) 772-780;
You have access
Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression.
E B Haddad, J Rousell, J C Mak and P J Barnes

Molecular Pharmacology May 1996, 49 (5) 781-787;
You have access
Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
A J Freemerman, A J Turner, M J Birrer, E Szabo, K Valerie and S Grant

Molecular Pharmacology May 1996, 49 (5) 788-795;
You have access
Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450.
T J Carlson and R E Billings

Molecular Pharmacology May 1996, 49 (5) 796-801;
You have access
Expression of cytochrome P4502E1 in rat fetal hepatocyte culture.
D Wu and A I Cederbaum

Molecular Pharmacology May 1996, 49 (5) 802-807;
You have access
Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
D MacDonald, S C Silberman, J A Lowe, S E Drozda, S E Leeman and N D Boyd

Molecular Pharmacology May 1996, 49 (5) 808-813;
You have access
1-Hydroxyethyl radical formation during NADPH- and NADH-dependent oxidation of ethanol by human liver microsomes.
D N Rao, M X Yang, J M Lasker and A I Cederbaum

Molecular Pharmacology May 1996, 49 (5) 814-821;
You have access
Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam.
F Impagnatiello, C Pesold, P Longone, H Caruncho, J M Fritschy, E Costa and A Guidotti

Molecular Pharmacology May 1996, 49 (5) 822-831;
You have access
Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
Y H Ling, A K el-Naggar, W Priebe and R Perez-Soler

Molecular Pharmacology May 1996, 49 (5) 832-841;
You have access
Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
H M Beere, C M Chresta and J A Hickman

Molecular Pharmacology May 1996, 49 (5) 842-851;
You have access
Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study.
M B Ghasemzadeh, S Sharma, D J Surmeier, J H Eberwine and M F Chesselet

Molecular Pharmacology May 1996, 49 (5) 852-859;
You have access
Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B.
M Goto, K Yamada, K Katayama and I Tanaka

Molecular Pharmacology May 1996, 49 (5) 860-873;
You have access
Ahr locus phenotype in congenic mice influences hepatic and pulmonary DNA adduct levels of 2-amino-3-methylimidazo[4,5-f]quinoline in the absence of cytochrome P450 induction.
P V Nerurkar, H A Schut, L M Anderson, C W Riggs, L W Fornwald, C D Davis, E G Snyderwine, S S Thorgeirsson, W W Weber, J M Rice and G N Levy

Molecular Pharmacology May 1996, 49 (5) 874-881;
You have access
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
J Balzarini, H Pelemans, M J Pérez-Pérez, A San-Félix, M J Camarasa, E De Clercq and A Karlsson

Molecular Pharmacology May 1996, 49 (5) 882-890;
You have access
A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2.
Z H Song and T I Bonner

Molecular Pharmacology May 1996, 49 (5) 891-896;
You have access
3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.
J E Hawkinson, J A Drewe, C L Kimbrough, J S Chen, D J Hogenkamp, N C Lan, K W Gee, K Z Shen, E R Whittemore and R M Woodward

Molecular Pharmacology May 1996, 49 (5) 897-906;
You have access
Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of beta gamma subunits in transducing enhanced activity of the type VI isoform.
J M Thomas and B B Hoffman

Molecular Pharmacology May 1996, 49 (5) 907-914;
You have access
Interaction of full and partial agonists of the A1 adenosine receptor with receptor/G protein complexes in rat brain membranes.
A Lorenzen, L Guerra, H Vogt and U Schwabe

Molecular Pharmacology May 1996, 49 (5) 915-926;
You have access
Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor.
K E McCrea and S J Hill

Molecular Pharmacology May 1996, 49 (5) 927-937;
You have access
Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors.
G H Fletcher and J H Steinbach

Molecular Pharmacology May 1996, 49 (5) 938-947;